Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation

International Journal of COPD

Volumn 4, Issue 1, 2009, Pages 101-109

  Bathoorn, Erik ^a   Liesker, Jeroen J W ^a   Postma, Dirkje S ^a   Koëter, Gerard H ^a   van der Toorn, Marco ^a   van der Heide, Sicco ^a   Ross, H Alec ^b   van Oosterhout, Antoon J M ^a   Kerstjens, Huib A M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Inflammation; Sputum induction

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; MESSENGER RNA; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LYMPHOCYTE COUNT; MALE; NEUTROPHIL COUNT; OUTPATIENT; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; SPUTUM LEVEL;

EID: 66149171754     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/copd.s4854     Document Type: Article

References (46)

1. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852.
2. Schmier JK, Halpern MT, Higashi MK, Bakst A. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual Life Res. 2005;14(2):329-347.
3. McGuire A, Irwin DE, Fenn P et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health. 2001;4(5):370-375.
4. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl 2):398S-401S.
5. Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet. 1998;352(9126):467-473.
6. Global Strategy for the Diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease; updated 2006. available from http://www.goldcopd.com. 2006.
7. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204.
8. Hurst JR, Donaldson GC, Perea WR, et al. Utility of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867-874.
9. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600-607.
10. Bathoorn D. Change in inflammation during COPD exacerbations. Eur Respir J. 2005;26 Suppl 49:15s.
11. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8(8):1398-1420.
12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5-40.
13. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003;28;1(1):13.
14. Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med. 1997;155(5):1501-1508.
15. Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koeter GH, Postma DS. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J. 2000;15(1):109-115.
16. Meijer RJ, Kerstjens HA, Arends LR, Kauffman HF, Koeter GH, Postma DS. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax. 1999;54(10):894-899.
17. Renkema TE, Postma DS, Noordhoek JA, Sluiter HJ, Kauffman HF. In vitro release of neutrophil elastase, myeloperoxidase and betaglucuronidase in patients with emphysema and healthy subjects. Eur Respir J. 1991;4(10):1237-1244.
18. Geckler RW, Gremillion DH, McAllister CK, Ellenbogen C. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol. 1977;6(4):396-399.
19. Borger P, Vellenga E, Gringhuis SI, et al. Prostaglandin E2 differentially modulates IL-5 gene expression in activated human T lymphocytes depending on the costimulatory signal. J Allergy Clin Immunol. 1998;101(2 Pt 1):231-240.
20. Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res. 2006;7:62.
21. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(2): 349-355.
22. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-120.
23. Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J. 2005;25(4):640-646.
24. Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168(8):968-975.
25. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1646-1652.
26. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114-1121.
27. Pizzichini MM, Popov TA, Efthimiadis A, et al. Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med. 1996;154(4 Pt 1):866-869.
28. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;173(7):736-743.
29. Bathoorn E, Liesker JJ, Postma DS, et al. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations. COPD. 2008;5(5):282-290.
30. Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA, Warner JA. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 2005;6:151.
31. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17(6):1112-1119.
32. Roland M, Bhowmik A, Sapsford RJ, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax. 2001;56(1):30-35.
33. Majori M, Corradi M, Caminati A, Cacciani G, Bertacco S, Pesci A. Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1999;103(3 Pt 1):458-462.
34. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164(3):469-473.
35. van der Strate BW, Postma DS, Brandsma CA, et al. Cigarette Smokeinduced Emphysema: A Role for the B Cell? Am J Respir Crit Care Med. 2006;173(7):751-758.
36. Gosman MM, Willemse BW, Jansen DF, et al. Increased number of B-cells in bronchial biopsies in COPD. Eur Respir J. 2006;27(1):60-64.
37. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653.
38. Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev. 1997;159:95-103.
39. Coro ES, Chang WL, Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol. 2006;176(7):4343-4351.
40. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J. 2001;17(5):946-953.
41. Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax. 2003;58(10):832-834.
42. Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J. 2005;25(4):640-646.
43. Zagai U, Skold CM, Trulson A, Venge P, Lundahl J. The effect of eosinophils on collagen gel contraction and implications for tissue remodelling. Clin Exp Immunol. 2004;135(3):427-433.
44. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(1):716-718.
45. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618-1623.
46. Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(5):491-497.